- Recent Facility Upgrades Expand Company’s Leadership Position with World’s Largest EU-GMP Certified Cannabis Facility; International Export Sales Grew 171% as Demand Continues to Increase
- Consolidated Net Sales Increased 27% to
$50.2 Million with Net Income of$2.9 Million or$0.03 Per Share - Adjusted EBITDA from Continuing Operations Increased 118% to
$9.9 Million or 20% of Sales Netherlands and Canadian Expansions Expected to Contribute toStronger Sales During 2H’26- After
$6.4 Million of Share Repurchases,$9.2 Million in Capital Expenditures, and$15.0 Million of Income Taxes Paid in Q1, Company Expects to Grow its Cash Balance from Operating Cash Flow through Year End
Notice Regarding Changes to Segment Financial Reporting
During the first quarter of 2026, the Company realigned its structure toward a unified cannabis operating model, including changes and additions to its leadership team, to gain operational efficiencies and better align resources with customer and market opportunities. The Company's operations are now organized, managed and classified into one reportable segment—Cannabis. The Company’s remaining operations are not reportable segments, as defined by the applicable accounting standard, and are classified as Other. Corporate expenses reflect the operations costs that are not allocated to the Company's operating units.
Management Commentary
President and Chief Executive Officer
“In Canada, we’re continuing to benefit from efforts to shift our business toward higher-margin products, growing market share in targeted and profitable product categories, and our Pure Sunfarms brand has now increased its share of dried flower formats for 15 consecutive months. It was also a record quarter of international medical export sales, which grew 171% year-over-year and 60% sequentially, supported by increasing demand for Village Farms’ EU-GMP compliant products, particularly in
“After making recent facility upgrades at our 4.8 million square foot production campus in
“We remain in an excellent position to continue scaling profitably with increasing global demand, and believe the strength of our balance sheet and cash generation profile will enable flexibility to make additional accretive organic and acquisitive growth investments. We have a lot of attractive opportunities emerging for us in the
First Quarter 2026 Financial Highlights
(All comparable periods are for the first quarter of 2025 unless otherwise stated)
Cannabis Operations
- Net sales increased 27% to
$49.7 million from$39.2 million ; - International export sales increased 171%; Canadian retail branded sales increased 5%;
Netherlands sales increased 448%; - Gross margin increased to 43% from 39% in the prior year period;
- Net income improved to
$4.8 million from$2.8 million , an increase of 68% year-over-year; - Adjusted EBITDA from continuing operations increased 48% to
$10.2 million or 20.5% of sales, compared to$6.9 million or 17.5% of sales in the prior year period; - Cash flow used in operations was
($11.8) million , driven by the impact of US$15.0 million of Canadian income taxes paid in Q1 2026 related to tax obligations from the previous fiscal year.
- Surpassed the high end of its targeted gross margin range for cannabis of 30-40% for the fourth consecutive quarter; and recorded positive EPS from continuing operations for the fourth consecutive quarter.
- Maintained a top five overall market share position in the Canadian market, and continued to hold the number one market share position in dried flower. The Company’s Pure Sunfarms brand expanded its market share position for the 15th consecutive month in April, reflecting improving consumer preference for the Company’s strains following recent introductions of packaging innovations that showcase the Company’s flower quality and aromas1.
- International export sales from
Canada increased 171% year-over-year to a record high of$14.6 million . The Company believes it remains the largest exporter of medical cannabis toEurope , with three of the top five leading cultivars inGermany and four of the top 10 through our distribution partners2. - The Company recently completed facility upgrades at its 4.8 million square foot production campus in
Delta, British Columbia , the Company now believes it operates the world’s largest EU-GMP certified cannabis facility. - Began planting the first half of its
Delta 2 greenhouse expansion inCanada , which is expected to begin contributing to sales late in the second quarter of 2026. The full expansion is expected to yield an incremental 40 metric tonnes of annualized cannabis production, expanding Canadian capacity by approximately 33% once completed in 2027. - The Company expects to commence all operations at its Phase II facility in
the Netherlands during Q2 and ramp to full capacity by the end of 2026. Once operating at full capacity, the Phase II facility is expected to quintuple totalNetherlands production to approximately 10 metric tonnes annually.
Corporate and Other
- Began a succession planning process for Chief Financial Officer
Steve Ruffini , who will remain an employee of the Company to help ensure a smooth transition of CFO responsibilities, and will be appointed to a new leadership position focused on evaluating strategic M&A opportunities. - Favorably amended and extended its loan with its long-term lender,
Farm Credit Canada (FCC). The Company improved the interest rate on the loan by 50 basis points and extended the maturity date by three years and nine months toFebruary 3, 2031 . The FCC loan carries a variable interest rate currently below 7.0%, with a current balance of US$15.4 million . - On
April 23, 2026 ,President Trump issued an executive order to (1) immediately place both FDA-approved products containing marijuana and marijuana products regulated by a state medical marijuana license in Schedule III of the Controlled Substances Act, and (2) initiate an expedited administrative hearing process to consider the broader rescheduling of marijuana from Schedule I to Schedule III, which is expected to commence onJune 29, 2026 . The Company believes it is poised to benefit fromPresident Trump's Executive Order, which, if the broader rescheduling is enacted as anticipated, would represent a consequential step in modernizingU.S. cannabis policy and support the development of a regulatory framework more aligned with international drug policies.
1. Based on estimated retail sales from HiFyre, other third parties and provincial boards.
2. Based on Company estimates and rankings compiled by German outlet Flowzz.
Conference Call
Village Farms’ management team will host a conference call to discuss its first quarter 2026 financial results today,
The live question and answer session will be limited to analysts; however, others are invited to submit questions ahead of the conference call via email at investorrelations@villagefarms.com. Management will address questions received via email during the question-and-answer session as time permits.
About
In
In
Contact Information
Senior Vice President, Corporate Affairs Phone: (407) 936-1190 ext. 328 Email: sgibbons@villagefarms.com Phone: (416) 519-4196 Email: lawrence.chamberlain@loderockadvisors.com |
Cannabis Performance Summary
| ($ US thousands, except % metrics) | Three Months Ended | ||||||||||
| 2026 | 2025 | Change | |||||||||
| Total | $ | 49,744 | $ | 39,227 | 27% | ||||||
| Total Cost of Sales | $ | 28,436 | $ | 23,958 | 19% | ||||||
| Gross Profit | $ | 21,308 | $ | 15,269 | 40% | ||||||
| Gross Margin % | 43% | 39% | 10% | ||||||||
| SG&A | $ | 14,820 | $ | 11,736 | 26% | ||||||
| Net income | $ | 4,780 | $ | 2,848 | 68% | ||||||
| Adjusted EBITDA from Continuing Operations(1) | $ | 10,196 | $ | 6,889 | 48% | ||||||
| Adjusted EBITDA from Continuing Operations Margin(1) | 20% | 18% | 11% | ||||||||
| Cash flow from Operations | $ | (11,810 | ) | $ | 2,886 | NM | |||||
(1) Adjusted EBITDA from continuing operations is not a recognized earnings measure and does not have a standardized meaning prescribed by GAAP. Therefore, Adjusted EBITDA from continuing operations may not be comparable to similar measures presented by other issuers. Management believes that Adjusted EBITDA from continuing operations is a useful supplemental measure in evaluating the performance of the Company because it excludes non-recurring and other items that do not reflect our business performance. Adjusted EBITDA from continuing operations includes the Company’s 80% interest in Rose LifeScience.
Composition of Sales by Channel
| For the Three Months Ended | ||||||||
| Classification | 2026 | 2025 | ||||||
| Cannabis: | ||||||||
| Canadian Branded(1) | $ | 23,848 | $ | 22,761 | ||||
| Canadian Non-Branded | 5,377 | 6,279 | ||||||
| International Exports | 14,581 | 5,388 | ||||||
| 3,133 | 3,904 | |||||||
| Netherlands Branded | 2,663 | 486 | ||||||
| Other | 142 | 409 | ||||||
| Total Cannabis | 49,744 | 39,227 | ||||||
| Other: | ||||||||
| Produce | 108 | 27 | ||||||
| Clean Energy | 386 | 426 | ||||||
| Total Revenue | $ | 50,238 | $ | 39,680 | ||||
(1) Canadian Branded revenues are shown net of excise tax on products. Excise tax on products was
Presentation of Financial Results
The Company’s financial statements for the three months ended
RESULTS OF OPERATIONS
(In thousands of
| Three Months Ended | |||||||
| 2026 | 2025 | ||||||
| Sales | $ | 50,238 | $ | 39,680 | |||
| Cost of sales | (29,252 | ) | (25,501 | ) | |||
| Gross profit | 20,986 | 14,179 | |||||
| Selling, general and administrative expenses | (15,942 | ) | (14,619 | ) | |||
| Interest expense | (523 | ) | (701 | ) | |||
| Interest income | 608 | 75 | |||||
| Foreign exchange (loss) gain | (548 | ) | (84 | ) | |||
| Other (loss) income | (184 | ) | 22 | ||||
| Income (loss) before taxes and equity method investment income | 4,397 | (1,128 | ) | ||||
| Provision for income taxes | (1,668 | ) | (983 | ) | |||
| Equity method investment income, net of tax | — | — | |||||
| Income (loss) from continuing operations | 2,729 | (2,111 | ) | ||||
| (Loss) Income from discontinued operations, net of tax | — | (5,004 | ) | ||||
| Income (loss) including non-controlling interests | 2,729 | (7,115 | ) | ||||
| Less: net (income) loss attributable to non-controlling interests, net of tax | 188 | 412 | |||||
| Net income (loss) attributable to | $ | 2,917 | $ | (6,703 | ) | ||
| Adjusted EBITDA from continuing operations(1) | $ | 9,890 | $ | 4,546 | |||
| Basic income (loss) per share attributable to | |||||||
| Continuing operations | $ | 0.03 | $ | (0.02 | ) | ||
| Discontinued operations | - | (0.04 | ) | ||||
| Basic income (loss) per share attributable to | $ | 0.03 | $ | (0.06 | ) | ||
| Diluted income (loss) per share attributable to | |||||||
| Continuing operations | $ | 0.02 | $ | (0.02 | ) | ||
| Discontinued operations | $ | — | $ | (0.04 | ) | ||
| Diluted income (loss) per share attributable to | $ | 0.02 | $ | (0.06 | ) | ||
(1) Adjusted EBITDA from continuing operations is not a recognized earnings measure and does not have a standardized meaning prescribed by GAAP. Therefore, Adjusted EBITDA from continuing operations may not be comparable to similar measures presented by other issuers. Management believes that Adjusted EBITDA from continuing operations is a useful supplemental measure in evaluating the performance of the Company because it excludes non-recurring and other items that do not reflect our business performance. Adjusted EBITDA from continuing operations includes the Company’s 80% interest in Rose LifeScience.
We caution that our results of operations for the three months ended
SEGMENTED RESULTS OF OPERATIONS
(In thousands of
| For The Three Months Ended | |||||||||||||||
| Cannabis | Other | Corporate | Total | ||||||||||||
| Sales | $ | 49,744 | $ | 494 | $ | — | $ | 50,238 | |||||||
| Cost of sales | (28,436 | ) | (816 | ) | — | (29,252 | ) | ||||||||
| Selling, general and administrative expenses | (14,820 | ) | (512 | ) | (610 | ) | (15,942 | ) | |||||||
| Other expense, net | (311 | ) | (222 | ) | (114 | ) | (647 | ) | |||||||
| Income (loss) before taxes and equity method investment income | 6,177 | (1,056 | ) | (724 | ) | 4,397 | |||||||||
| Provision for income taxes | (1,585 | ) | (83 | ) | — | (1,668 | ) | ||||||||
| Equity method investment income, net of tax | — | — | — | — | |||||||||||
| Income (loss) including non-controlling interests | 4,592 | (1,139 | ) | (724 | ) | 2,729 | |||||||||
| Less: net loss attributable to non-controlling interests, net of tax | 188 | — | — | 188 | |||||||||||
| Net income (loss) | $ | 4,780 | $ | (1,139 | ) | $ | (724 | ) | $ | 2,917 | |||||
| Adjusted EBITDA from Continuing Operations(1) | $ | 10,196 | $ | (23 | ) | $ | (283 | ) | $ | 9,890 | |||||
| Basic income (loss) per share | $ | 0.05 | $ | (0.01 | ) | $ | (0.01 | ) | $ | 0.03 | |||||
| Diluted income (loss) per share | $ | 0.04 | $ | (0.01 | ) | $ | (0.01 | ) | $ | 0.02 | |||||
| For The Three Months Ended | |||||||||||||||
| Cannabis | Other | Corporate | Total | ||||||||||||
| Sales | $ | 39,227 | $ | 453 | $ | — | $ | 39,680 | |||||||
| Cost of sales | (23,958 | ) | (1,543 | ) | — | (25,501 | ) | ||||||||
| Selling, general and administrative expenses | (11,736 | ) | (743 | ) | (2,140 | ) | (14,619 | ) | |||||||
| Other (expense) income, net | (202 | ) | (526 | ) | 40 | (688 | ) | ||||||||
| Income (loss) before taxes and equity method investment income | 3,331 | (2,359 | ) | (2,100 | ) | (1,128 | ) | ||||||||
| Provision for income taxes | (895 | ) | (69 | ) | (19 | ) | (983 | ) | |||||||
| Equity method investment income, net of tax | — | — | — | — | |||||||||||
| Income (loss) from continuing operations | 2,436 | (2,428 | ) | (2,119 | ) | (2,111 | ) | ||||||||
| Income (loss) from discontinued operations, net of tax | — | (5,004 | ) | — | (5,004 | ) | |||||||||
| Income (loss) including non-controlling interests | 2,436 | (7,432 | ) | (2,119 | ) | (7,115 | ) | ||||||||
| Less: net loss attributable to non-controlling interests, net of tax | 412 | — | — | 412 | |||||||||||
| Net income (loss) | $ | 2,848 | $ | (7,432 | ) | $ | (2,119 | ) | $ | (6,703 | ) | ||||
| Adjusted EBITDA from Continuing Operations(1) | $ | 6,889 | $ | (332 | ) | $ | (2,011 | ) | $ | 4,546 | |||||
| Basic income (loss) per share from continuing operations | $ | 0.03 | $ | (0.03 | ) | $ | (0.02 | ) | $ | (0.02 | ) | ||||
| Basic income per share from discontinued operations | $ | - | $ | (0.04 | ) | $ | - | $ | (0.04 | ) | |||||
| Basic income (loss) per share | $ | 0.03 | $ | (0.07 | ) | $ | (0.02 | ) | $ | (0.06 | ) | ||||
| Diluted income (loss) per share from continuing operations | $ | 0.03 | $ | (0.03 | ) | $ | (0.02 | ) | $ | (0.02 | ) | ||||
| Diluted income per share from discontinued operations | $ | - | $ | (0.04 | ) | $ | - | $ | (0.04 | ) | |||||
| Diluted income (loss) per share | $ | 0.03 | $ | (0.07 | ) | $ | (0.02 | ) | $ | (0.06 | ) | ||||
(1) Adjusted EBITDA from continuing operations is not a recognized earnings measure and does not have a standardized meaning prescribed by GAAP. Therefore, Adjusted EBITDA from continuing operations presented for these segments may not be comparable to similar measures presented by other issuers. Management believes that Adjusted EBITDA from continuing operations is a useful supplemental measure in evaluating the performance of the Company because it excludes non-recurring and other items that do not reflect the underlying business performance of the Company.
Reconciliation of Adjusted EBITDA from Continuing Operations to Net Income (Loss)
The following tables reflect a reconciliation of Adjusted EBITDA from continuing operations to net income (loss) from continuing operations, as presented by the Company:
| For The Three Months Ended | |||||||||||||||
| (in thousands of | Cannabis | Other | Corporate | Total | |||||||||||
| Net income (loss) from continuing operations | $ | 4,780 | $ | (1,139 | ) | $ | (724 | ) | $ | 2,917 | |||||
| Add: | |||||||||||||||
| Amortization and depreciation | 3,502 | 777 | 24 | 4,303 | |||||||||||
| Foreign currency exchange (gain) loss | 75 | 80 | 393 | 548 | |||||||||||
| Interest expense (income), net | 19 | 176 | (280 | ) | (85 | ) | |||||||||
| Provision for income taxes | 1,585 | 83 | — | 1,668 | |||||||||||
| Share-based compensation | 72 | — | 304 | 376 | |||||||||||
| Deferred financing fees | 72 | — | — | 72 | |||||||||||
| Loss on disposal of assets | 118 | — | — | 118 | |||||||||||
| Adjustments attributable to non-controlling interest | (27 | ) | — | — | (27 | ) | |||||||||
| Adjusted EBITDA from continuing operations(1) | $ | 10,196 | $ | (23 | ) | $ | (283 | ) | $ | 9,890 | |||||
| For The Three Months Ended | |||||||||||||||
| (in thousands of | Cannabis | Other | Corporate | Total | |||||||||||
| Net income (loss) from continuing operations | $ | 2,848 | $ | (2,428 | ) | $ | (2,119 | ) | $ | (1,699 | ) | ||||
| Add: | |||||||||||||||
| Amortization and depreciation | 2,938 | 1,457 | 44 | 4,439 | |||||||||||
| Foreign currency exchange loss (gain) | (51 | ) | 48 | (15 | ) | (18 | ) | ||||||||
| Interest expense (income), net | 141 | 509 | (24 | ) | 626 | ||||||||||
| Provision for (recovery of) income taxes | 895 | 69 | 19 | 983 | |||||||||||
| Share-based compensation | 48 | 13 | 84 | 145 | |||||||||||
| Adjustments attributable to non-controlling interest | 70 | — | — | 70 | |||||||||||
| Adjusted EBITDA from continuing operations(1) | $ | 6,889 | $ | (332 | ) | $ | (2,011 | ) | $ | 4,546 | |||||
(1) Adjusted EBITDA from continuing operations is not a recognized earnings measure and does not have a standardized meaning prescribed by GAAP. Therefore, Adjusted EBITDA from continuing operations presented for these segments may not be comparable to similar measures presented by other issuers. Management believes that Adjusted EBITDA from continuing operations is a useful supplemental measure in evaluating the performance of the Company because it excludes non-recurring and other items that do not reflect the underlying business performance of the Company.
This press release is intended to be read in conjunction with the Company’s Quarterly Report on Form 10-Q for the three months ended
Cautionary Statement Regarding Forward-Looking Information
As used in this Press Release, the terms “Village Farms”, “Village Farms International”, the “Company”, “we”, “us”, “our” and similar references refer to
This Press Release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the
The Company has based these forward-looking statements on factors and assumptions about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. Although the forward-looking statements contained in this Press Release are based upon assumptions that management believes are reasonable based on information currently available to management, there can be no assurance that actual results will be consistent with these forward-looking statements. Forward-looking statements necessarily involve known and unknown risks and uncertainties, many of which are beyond the Company's control, which may cause the Company's or the industry's actual results, performance, achievements, prospects and opportunities in future periods to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among other things, the factors contained in the Company's filings with securities regulators, including this Press Release and the Company’s most recently filed annual report on Form 10-K.
When relying on forward-looking statements to make decisions, the Company cautions readers not to place undue reliance on these statements, as forward-looking statements involve significant risks and uncertainties and should not be read as guarantees of future results, performance, achievements, prospects and opportunities. The forward-looking statements made in this Press Release relate only to events or information as of the date on which the statements are made in this Press Release. Except as required by law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.
Condensed Consolidated Statements of Financial Position (In thousands of (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 50,468 | $ | 81,189 | ||||
| Restricted cash | 5,059 | 5,063 | ||||||
| Trade receivables, net | 26,643 | 23,151 | ||||||
| Inventories, net | 44,420 | 41,519 | ||||||
| Other receivables | 1,374 | 324 | ||||||
| Prepaid expenses and deposits | 3,965 | 3,191 | ||||||
| Total current assets | 131,929 | 154,437 | ||||||
| Non-current assets | ||||||||
| Property, plant and equipment, net | 189,560 | 185,712 | ||||||
| Investments | 6,276 | 6,276 | ||||||
| 43,653 | 44,365 | |||||||
| Intangibles, net | 22,458 | 23,647 | ||||||
| Deferred tax asset | 611 | 694 | ||||||
| Right-of-use assets | 3,821 | 4,066 | ||||||
| Other assets | 2,576 | 3,899 | ||||||
| Total assets | $ | 400,884 | $ | 423,096 | ||||
| LIABILITIES | ||||||||
| Current liabilities | ||||||||
| Trade payables | $ | 9,948 | $ | 15,747 | ||||
| Current maturities of long-term debt | 4,973 | 4,885 | ||||||
| Accrued sales taxes | 7,409 | 8,695 | ||||||
| Accrued liabilities | 17,117 | 13,960 | ||||||
| Lease liabilities - current | 1,198 | 1,198 | ||||||
| Income tax payable | — | 12,151 | ||||||
| Other current liabilities | 2,456 | 1,950 | ||||||
| Total current liabilities | 43,101 | 58,586 | ||||||
| Non-current liabilities | ||||||||
| Long-term debt | 30,776 | 28,769 | ||||||
| Deferred tax liability | 17,711 | 18,494 | ||||||
| Lease liabilities - non-current | 3,530 | 3,855 | ||||||
| Other non-current liabilities | 1,979 | 3,330 | ||||||
| Total liabilities | 97,097 | 113,034 | ||||||
| MEZZANINE EQUITY | ||||||||
| Redeemable non-controlling interest | 9,819 | 10,164 | ||||||
| SHAREHOLDERS’ EQUITY | ||||||||
| Common stock, no par value per share - unlimited shares authorized; 114,048,023 shares issued and outstanding at | 392,898 | 392,380 | ||||||
| Additional paid in capital | 23,382 | 29,374 | ||||||
| Accumulated other comprehensive loss | (12,654 | ) | (9,281 | ) | ||||
| Retained earnings | (109,658 | ) | (112,575 | ) | ||||
| Total shareholders’ equity | 293,968 | 299,898 | ||||||
| Total liabilities, mezzanine equity and shareholders’ equity | $ | 400,884 | $ | 423,096 | ||||
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (In thousands of (Unaudited) | |||||||
| Three Months Ended | |||||||
| 2026 | 2025 | ||||||
| Sales | $ | 50,238 | $ | 39,680 | |||
| Cost of sales | (29,252 | ) | (25,501 | ) | |||
| Gross profit | 20,986 | 14,179 | |||||
| Selling, general and administrative expenses | (15,942 | ) | (14,619 | ) | |||
| Interest expense | (523 | ) | (701 | ) | |||
| Interest income | 608 | 75 | |||||
| Foreign exchange (loss) gain | (548 | ) | (84 | ) | |||
| Other (loss) income | (184 | ) | 22 | ||||
| Income (loss) before taxes and equity method investment income | 4,397 | (1,128 | ) | ||||
| Provision for income taxes | (1,668 | ) | (983 | ) | |||
| Equity method investment income, net of tax | — | — | |||||
| Income (loss) from continuing operations | 2,729 | (2,111 | ) | ||||
| (Loss) Income from discontinued operations, net of tax | — | (5,004 | ) | ||||
| Income (loss) including non-controlling interests | 2,729 | (7,115 | ) | ||||
| Less: net (income) loss attributable to non-controlling interests, net of tax | 188 | 412 | |||||
| Net income (loss) attributable to | $ | 2,917 | $ | (6,703 | ) | ||
| Basic income (loss) per share attributable to | |||||||
| Continuing operations | $ | 0.03 | $ | (0.02 | ) | ||
| Discontinued operations | - | (0.04 | ) | ||||
| Basic income (loss) per share attributable to | $ | 0.03 | $ | (0.06 | ) | ||
| Diluted income (loss) per share attributable to | |||||||
| Continuing operations | $ | 0.02 | $ | (0.02 | ) | ||
| Discontinued operations | $ | — | $ | (0.04 | ) | ||
| Diluted income (loss) per share attributable to | $ | 0.02 | $ | (0.06 | ) | ||
Condensed Consolidated Statements of Cash Flows (In thousands of (Unaudited) | ||||||||
| Three Months Ended | ||||||||
| 2026 | 2025 | |||||||
| Cash flows (used in) provided by operating activities: | ||||||||
| Income (loss) from continuing operations including non-controlling interests | $ | 2,729 | $ | (2,111 | ) | |||
| Adjustments to reconcile net income (loss) attributable to | ||||||||
| Depreciation and amortization | 4,303 | 4,439 | ||||||
| Amortization of deferred charges | 72 | — | ||||||
| Interest expense | 523 | 701 | ||||||
| Interest paid on long-term debt | (394 | ) | (794 | ) | ||||
| Unrealized foreign exchange (gain) loss | 71 | 49 | ||||||
| Loss on disposal of assets | 118 | — | ||||||
| Non-cash lease expense | 244 | 196 | ||||||
| Share-based compensation | 376 | 145 | ||||||
| Deferred income taxes | (415 | ) | (663 | ) | ||||
| Changes in non-cash working capital items | (24,390 | ) | (5,729 | ) | ||||
| Net cash used in operating activities from continuing operations | (16,763 | ) | (3,767 | ) | ||||
| Cash flows (used in) provided by investing activities: | ||||||||
| Purchases of property, plant and equipment | (9,227 | ) | (1,249 | ) | ||||
| Other investing activities | — | (300 | ) | |||||
| Net cash used in investing activities from continuing operations | (9,227 | ) | (1,549 | ) | ||||
| Cash flows (used in) provided by financing activities: | ||||||||
| Proceeds from borrowings | 3,589 | — | ||||||
| Repayments on borrowings | (1,208 | ) | (1,384 | ) | ||||
| Share repurchases | (6,368 | ) | — | |||||
| Proceeds from exercise of warrants and options | 469 | — | ||||||
| Other financing activities | (186 | ) | — | |||||
| Net cash used in financing activities from continuing operations | (3,704 | ) | (1,384 | ) | ||||
| Discontinued Operations | ||||||||
| Net cash (used in) provided by operating activities from discontinued operations | — | (2,610 | ) | |||||
| Net cash (used in) provided by investing activities from discontinued operations | — | (1,290 | ) | |||||
| Net cash (used in) provided by financing activities from discontinued operations | — | 1,000 | ||||||
| Net cash flows used in discontinued operations | — | (2,900 | ) | |||||
| Effect of exchange rate changes on cash and cash equivalents | (1,031 | ) | 93 | |||||
| Net increase (decrease) in cash, cash equivalents and restricted cash | (30,725 | ) | (9,507 | ) | ||||
| Cash, cash equivalents and restricted cash, beginning of period | 86,252 | 24,631 | ||||||
| Cash, cash equivalents and restricted cash, end of period | $ | 55,527 | $ | 15,124 | ||||
Source: